• Phillip Reece is a consultant expert with over 30 years experience in the research and development of human pharmaceuticals
• Trained initially in organic and medicinal chemistry and then specialized in pharmacokinetics
• 12 years experience in clinical pharmacology in an Australian teaching Hospital before joining Astra Pharmaceuticals and then Parke Davis, Sydney, Australia
• Director of Clinical Pharmacology, Parke Davis, Ann Arbor, MI, USA responsible for the development of CNS drugs
• Inaugural Director of Research and Development at Biota Holdings, one of Australia’s leading biotechnology companies and founder of the influenza antiviral, zanamivir
• Senior industry roles including CEO of Boron Molecular, Chairman of Cryptopharma, and non-executive Director of EnGeneIC
• Consultant expert to lawyers engaged in one of Australia’s largest commercial litigation cases: communicated complex scientific issues to the legal team; assisted in preparation of questions for expert witnesses; prepared technical reports, chronologies and literature reviews for the case
• Consultant expert including experience as an expert witness in the areas of pharmaceutical development, clinical trials, pharmacokinetics, pharmacodynamics and intellectual property matters to biotechnology companies, pharmaceutical companies and law firms
• 67 scientific publications in the areas of human pharmacokinetics, clinical trials, respiratory antivirals particularly for influenza, anticancer drugs and antihypertensives; 3 book chapters and an inventor on three published patents
• Further details can be found on the refereed, international experts site, Intota at: http://www.intota.com/expert-consultant.asp?bioID=777929&perID=727493

SEE: Resume, FAQs, Publications, Presentations, Patents, Details of Recent Appointments